The pancreatic cancer patient received 109-5 × 1010 retroviral transduced CEA CAR T cells i.v. and seven doses IL-2 with cyclophosphamide and fludarabine preconditioning. All patients had adverse events with grade ≤ 2 and lack of prolonged CAR T cell persistence led to the premature termination of the trial. No objective clinical response observed although serum CEA level reduced in the pancreatic cancer patient (47). Here, CEACAM5 is linked to pancreatic neoplasm.